
Currently also: Chief Informatics and Technology Officer (CITO) at Pangea Botanica, London/UK and Berlin/Germany
Previous positions:
Director Digital Chemistry at NUVISAN Berlin
Associate Director Computational ADME and Safety (Clinical Pharmacology & Safety Sciences/Data Science and Artificial Intelligence - CPSS/DSAI) at AstraZeneca Cambridge
Co-founder of Healx Ltd.
Co-founder of PharmEnable Ltd.
- Committed to developing new life science data analysis methods (AI/ML/data science) and their application, primarily related to chemical biology, drug discovery and in silico toxicology
- Expertise comprises data ranging from chemical structure and gene expression data to phenotypic readouts and preclinical information, applied to both efficacy- and safety/tox-related questions
- Collaborating with academic research groups, as well as pharmaceutical, chemical, and consumer goods companies (Eli Lilly, AstraZeneca, GSK, BASF, Johnson&Johnson/Janssen, Unilever, ...)
- Co-founder/founding CTO and current SAB member of Healx Ltd. (data-driven drug repurposing for rare diseases, and beyond); co-founder of PharmEnable Ltd.; SAB member of Lhasa Ltd. (toxicology and metabolism prediction) and Cresset Ltd.
- Coordinator of the Computational & In Silico Toxicology Specialty Section of the British Toxicology Society (BTS)
- Steering Committee Member of the Cambridge Alliance on Medicines Safety (CAMS)
- Currently leading a group of ca. 15 PhD students, postdocs, project students and visitors at the Centre for Molecular Informatics at the University of Cambridge, https://www-cmi.ch.cam.ac.uk/centre-molecular-informatics
Publications
MOLPRINT 2D-based identification and synthesis of novel chromene based small molecules that target PLA2: Validation through chemo- and bioinformatics approaches
Rsc Advances
(2015)
5
89797
(doi: 10.1039/c5ra13085a)
Comparing global and local likelihood score thresholds in multiclass Laplacian-modified Naïve bayes protein target prediction
Combinatorial chemistry & high throughput screening
(2015)
18
323
Polypharmacology modelling using proteochemometrics (PCM): Recent methodological developments, applications to target families, and future prospects
RSC Medicinal Chemistry
(2015)
6
24
(doi: 10.1039/c4md00216d)
Novel synthetic coumarins that targets NF-κB in Hepatocellular carcinoma
Bioorg Med Chem Lett
(2014)
25
893
(doi: 10.1016/j.bmcl.2014.12.065)
Extending in silico mechanism-of-action analysis by annotating targets with pathways: application to cellular cytotoxicity readouts
Future medicinal chemistry
(2014)
6
2029
(doi: 10.4155/fmc.14.137)
Target Fishing: A Single-Label or Multi-Label Problem?
arXiv
(2014)
A community computational challenge to predict the activity of pairs of compounds.
Nature Biotechnology
(2014)
32
1213
(doi: 10.1038/nbt.3052)
Modelling ligand selectivity of serine proteases using integrative proteochemometric approaches improves model performance and allows the multi-target dependent interpretation of features
Integrative biology : quantitative biosciences from nano to macro
(2014)
6
1023
(doi: 10.1039/c4ib00175c)
Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
The Journal of biological chemistry
(2014)
289
34296
(doi: 10.1074/jbc.m114.601104)
Towards predictive resistance models for agrochemicals by combining chemical and protein similarity via proteochemometric modelling
Journal of Chemical Biology
(2014)
7
119
(doi: 10.1007/s12154-014-0112-2)
- ‹ previous
- Page 25